Targeting epidermal growth factor receptor (EGFR) is an appealing strategy for the treatment of NSCLC, because EGFR has been found to be expressed, sometimes strongly, in NSCLC (Franklin et al, 2002). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.